Myokardia Inc (MYOK) Insider Sells $125,100.00 in Stock

Myokardia Inc (NASDAQ:MYOK) insider Anastasios Gianakakos sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $41.70, for a total value of $125,100.00. Following the completion of the sale, the insider now owns 512,117 shares of the company’s stock, valued at approximately $21,355,278.90. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Anastasios Gianakakos also recently made the following trade(s):

  • On Thursday, December 21st, Anastasios Gianakakos sold 3,000 shares of Myokardia stock. The stock was sold at an average price of $41.09, for a total value of $123,270.00.
  • On Monday, November 6th, Anastasios Gianakakos sold 4,300 shares of Myokardia stock. The stock was sold at an average price of $40.23, for a total value of $172,989.00.

Myokardia Inc (NASDAQ MYOK) traded up $0.30 during trading on Friday, hitting $42.30. The company had a trading volume of 242,732 shares, compared to its average volume of 620,050. The company has a market cap of $1,502.91, a P/E ratio of -55.66 and a beta of 4.21. Myokardia Inc has a 1-year low of $10.55 and a 1-year high of $49.55.

Myokardia (NASDAQ:MYOK) last posted its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.42) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.42). The business had revenue of $5.63 million during the quarter, compared to the consensus estimate of $6.10 million. Myokardia had a negative return on equity of 14.92% and a negative net margin of 53.49%. Myokardia’s revenue was up 58.6% on a year-over-year basis. During the same quarter last year, the company earned ($0.35) EPS. sell-side analysts anticipate that Myokardia Inc will post -1.62 EPS for the current fiscal year.

A number of brokerages have commented on MYOK. Zacks Investment Research downgraded Myokardia from a “hold” rating to a “sell” rating in a research report on Wednesday. BidaskClub upgraded Myokardia from a “sell” rating to a “hold” rating in a research report on Tuesday, December 26th. Wedbush reiterated an “outperform” rating and issued a $51.00 price objective on shares of Myokardia in a research report on Wednesday, September 20th. ValuEngine downgraded Myokardia from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Finally, JPMorgan Chase & Co. began coverage on Myokardia in a research report on Tuesday, December 12th. They issued an “overweight” rating and a $54.00 price objective for the company. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. Myokardia has a consensus rating of “Hold” and a consensus target price of $54.83.

Several institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in shares of Myokardia by 11.5% during the 2nd quarter. Vanguard Group Inc. now owns 764,919 shares of the biotechnology company’s stock worth $10,020,000 after buying an additional 78,800 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Myokardia by 103.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 476,575 shares of the biotechnology company’s stock worth $6,243,000 after buying an additional 242,408 shares during the period. Wells Fargo & Company MN lifted its position in shares of Myokardia by 2,151.7% during the 3rd quarter. Wells Fargo & Company MN now owns 417,439 shares of the biotechnology company’s stock worth $17,887,000 after buying an additional 398,900 shares during the period. VHCP Management II LLC bought a new position in shares of Myokardia during the 3rd quarter worth approximately $11,355,000. Finally, RTW Investments LP bought a new position in shares of Myokardia during the 3rd quarter worth approximately $10,882,000. Institutional investors and hedge funds own 63.61% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Myokardia Inc (MYOK) Insider Sells $125,100.00 in Stock” was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.chaffeybreeze.com/2018/01/05/myokardia-inc-myok-insider-sells-125100-00-in-stock.html.

About Myokardia

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Insider Buying and Selling by Quarter for Myokardia (NASDAQ:MYOK)

Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply